3.3000 -0.02 (-0.60%)
After hours: 5:20PM EDT
|Bid||3.1800 x 800|
|Ask||3.3000 x 3100|
|Day's range||3.0600 - 3.3800|
|52-week range||1.3500 - 6.8200|
|Beta (5Y monthly)||2.06|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
IMV Inc. Re-establishes At-the-Market Facility
IMV has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announces that biomarkers associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac combination therapy will be presented at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting.